Synthesis and Characterization of Magnetic Nanocarriers for Cancer Drug Delivery by Momtazi, Leva
 Thesis for the Master’s Degree 
in Chemistry 
 
Leva Momtazi 
Synthesis and 
Characterization of 
Magnetic Nanocarriers 
for Cancer Drug 
Delivery 
 
60 study points 
DEPARTMENT OF CHEMISTRY 
Faculty of Mathematics 
 and Natural Sciences 
UNIVERSITY OF OSLO 
January 2014 
Page | i 
 
Acknowledgment  
My first and sincere appreciation goes to my supervisor, Professor Bo Nyström, for his 
patience, motivation, enthusiasm and immense knowledge. His guidance helped me in the 
time of research and writing of this thesis. I also would like to express my deep gratitude and 
respect to my co-supervisor Dr. Shahla Bagherifam whose advice and insight was valuable to 
me. In addition I would like to thank Dr. Reidar Lund for guiding my research in light 
scattering field. 
My special thanks to Dorna misaghian who did the HPLC measurements and 
Antje Hofgaard for cross-sectioning the cells. I would like to thank Professor Gunhild 
Mælandsmo who provided us with breast cancer cell line in the laboratory of the Radium 
Hospital. I wish to express my warm and sincere thanks to Arash Rayzan for helping me with 
illustrating the images in this thesis. Moreover, I would like to thank Professor Gareth 
Griffiths who gave feedback on cell uptake section of the thesis.  
I would like to thank my fellow labmates in the group: Sara Bekhradnia, Farinaz 
Kahnamouei, Golnaz Isapour, Elahe Jafari, Neda Khorshid, for the stimulating discussions, for 
the sleepless nights we were working together, and for all the fun we have had in the last 
two years.  
Last but not least I would like to thank my family: Maman, Baba, Vahid and Vesal to 
support me emotionally. My deepest appreciation is expressed to them for their love, 
understanding, and inspiration. 
Leva Momtazi 
University of Oslo 
January 2014 
 
Page | ii 
 
Abstract 
 A targetable nanocarrier consisting of a superpara-magnetic iron oxide (SPIO) core and 
a biodegradable and biocompatible polymer shell with the potential application in drug 
delivery system was prepared. The biodegradable and biocompatible poly (sebacic 
anhydride)-block-methylether-poly (ethylene glycol) (PSA-mPEG) was synthesized with poly 
condensation method to be used as the polymer shell for encapsulation of SPIO 
nanoparticles (SPIO-NPs). The synthesized block copolymer was charachterized by ܪ	
1 NMR, 
FTIR and GPC. The change in chemical structure and molecular weight of the polymer in PBS 
at 37℃ was studied by FTIR and GPC.  
The magnetic nanocarriers were synthesized by nanoprecipitation method and 
morphology of these nanocarriers was studied by transmission electron microscopy (TEM).  
The size and iron oxide content of the nanocarriers were studied by dynamic light scattering 
(DLS) and inductively coupled plasma spectroscopy (ICP-MS) respectively, to find an optimal 
carrier system for delivering therapeutic agents to the tumor site. 
The zeta potential measurement was conducted on nanoparticles in both deionized 
water and phosphate buffer saline (PBS) to evaluate the surface charge of the particles in 
these mediums. The hydrodynamic radius ( ܴℎ) of the SPIO loaded polymeric nanoparticles 
(SPIO-PNP) was measured over 30 days .The ܴℎ did not change considerably so it can be 
concluded that the particles were stable in this time period. 
The cytotoxicity of SPIO-PNPs, SPIO-NPs and blank polymeric nanoparticles were 
investigated on MDA-MB-231 breast cancer cell line. The cell viability was high (> 85%) for all 
three samples meaning that they did not induce toxicity. 
The internalization of SPIO-PNP in MDA-MB-231 cell line was confirmed by TEM. To 
make sure that the particles are confined within cells, the nanoparticle treated cells were 
fixed by glutaraldehyde and later cross sectioned.  
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1. Introduction  
The absence of specificity of drugs for tumor cells is a major problem of conventional 
chemotherapy in cancer treatment. In order to probe sufficient concentration at the tumor, 
large doses of drug need to be administrated causing the same cytotoxicity in both cancerous 
and healthy cells. To avoid damage to the healthy tissue, the administrated dose is usually 
less than optimal. The ideal treatment would provide enough therapeutic agents to eliminate 
all the cancer cells while leaving the healthy tissue intact. Drug delivery systems are a 
promising field of interest for tackling these challenges, and can be defined as the process of 
releasing a bioactive agents at a specific rate and a specific site [1-4]. 
1.2. Nanotechnology for drug-delivery 
By applying nanotechnology in drug delivery, small molecular weight drugs and also 
macromolecules such as protein, peptide or genes are delivered to the tissue of interest. 
Therapeutic agents are incorporated in biocompatible nanocomposites such as nanoparticles, 
nanocapsules and micellar systems in submicron size, and can provide targeted delivery of 
the drug to sustain drug effect in the target tissue and to protect the therapeutic agent from 
enzymatic degradation[5]. 
Among the different types of nanoparticles, superpara-magnetic iron oxide (SPIO) 
nanoparticles (NPs) are considered to be promising candidates in cancer therapy applications, 
as carriers in targeted drug delivery systems. Targeting these magnetic carriers by applying 
magnetic field can eliminate the complications caused by conventional cancer treatment, 
where the body is flushed by the drug[6].      
1.2.1. Nanoparticulate drug delivery systems formed by amphiphilic block 
copolymers 
Block copolymers with amphiphilic characteristics are macromolecules having a large 
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solubility difference between hydrophobic and hydrophilic segments with opposite affinities 
for an aqueous solvent. Block copolymers are at the center of attention in drug delivery 
systems because of their ability to form various types of nanoparticles. For drug delivery 
purposes, biocompatible and biodegradable polymers like polyesters, poly (amino acids) or 
poly anhydride can be used. These hydrophobic blocks are covalently bonded to 
biocompatible hydrophilic blocks like polyethylene glycol (PEG). Amphiphilic copolymers 
have the ability to form nanoparticles with different structures namely: micelles, 
nanospheres, nanocapsules and polymerases (Figure 1-1) [7]. 
 
Figure 1-1: General architecture of Nanoparticulate drug delivery systems formed by amphiphilic block 
copolymers  
1.2.1.1. Micelles 
Micellar self-association takes place above the critical micelle concentration (CMC) in a 
dilute solution of block copolymer in a specific solvent and at fixed temperature. In an 
aqueous solution, this phenomenon occurs because the amphiphilic copolymer orients itself 
in a way that hydrophobic blocks try to avoid the aqueous medium and achieve the minimum 
free energy level. Micellization of block copolymers is strongly dependent on temperature; 
therefore, for every concentration, a critical micelle concentration is specified. The self-
assembling process of polymer segments may generate a core-sell structure, in which the 
inner core is composed of hydrophobic segments. This architecture provides the space for 
solubilization of hydrophobic pharmaceutical agents; the micelle diameter ranges usually 
from 10 to 100 nm. Micelles are categorized as association or amphiphilic colloids but they 
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are not considered to be solid particles [7, 8]. 
1.2.2. Nanospheres 
Nanospheres are polymeric matrix systems in which a therapeutic agent is entrapped, 
encapsulated, absorbed or chemically bounded. In comparison with micelles, nanospheres 
usually exhibit broader size distribution and they are larger in size. Their diameter is often 
between 100 to 200 nm.  Nanospheres, in contrast to micelles, are classified as solid colloidal 
particles. Emulsification and nanoprecipitation are the two most important methods of 
nanosphere preparation. The latter involves dissolution of the block copolymer in an organic 
water miscible solvent followed by dispersion in aqueous media in presence or absence of 
surfactant. The water miscible solvent diffuses out in water; and as a consequence, the 
polymeric particle is formed [7]. 
1.2.3. Nanocapsules and polymersomes 
Nanocapsules are composed of a liquid or semi-liquid core surrounded by a solid 
material shell. A therapeutic agent can be confined to a reservoir or within a cavity 
surrounded by a polymer membrane or coating. Nanocapsules have an oil core with the 
ability to load a high amount of hydrophobic pharmaceutical agent[9]. For nanocapsule 
formation, the drug is first dissolved in a water-miscible organic solvent. An oil miscible with 
solvent but immiscible with mixture is added to this solution which is further dispersed in an 
aqueous media. Consequently, the solvent diffuses into the water and the nanocapsules are 
formed by aggregation of the polymer around the oil droplet [7, 10].  
Alternatively, polymersomes have the same architecture as nanocapsules but in 
contrast to nanocapsules, the core of vesicle is composed of an aqueous phase with the 
ability to encapsulate water-soluble drugs [7, 11].      
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1.3. Targeting the tumor site  
After intravenous administration, anti-cancer therapeutic agents are generally cleared 
from blood circulation rapidly and only a small fraction reaches the tumor site. Besides, 
reaching the tumor site does not guarantee a strong therapeutic effect because the drug may 
be cleared from the tumor too rapidly and may not be exposed to the tumor long enough. 
Another limitation is the physicochemical properties of the drug which makes entering the 
target cell difficult. In order to suppress these problems, targetable drug delivery systems 
have been developed. These systems utilize phenotypic properties of the diseased cells to 
concentrate drug at the target cells. Consequently, the drug is targeted to the tumor site and 
drug level in the tumor is enhanced [12]. 
1.3.1. Active targeting 
Tumor cells express many molecules on their surface in comparison with normal cells. 
These molecules can be detected by antibodies. Active targeting displays this characteristic 
of cancer cells to target the drugs to the tumor site. Active targeting, which is also known as 
ligand targeting, involves binding of ligands to the surface of drug carriers. These ligands, 
would then, bind to the molecules expressed on the cancer cells (Figure 1-2)[13]. Folic acid is 
one the most attractive molecules for targeting cancer cells. Primarily, because the folic acid 
receptor is overexpressed in many human cancer cells including ovary, brain, kidney, brain, 
myeloid and lung, and also, because of its high binding affinity, low immunogenicity, ease of 
modification, small size, stability during storage as well as its low cost [14].    
 
Figure 1-2 : ligand coated nanoparticles for active targeting of cancer cells 
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1.3.2. Passive targeting 
Passive targeting uses the enhanced permeability and retention effect (EPR) as one of 
the approaches to target nanoparticles to the tumor site. EPR is the result of the combination 
of leaky vascular and poor lymphatic drainage of a solid tumor. These leaky vessels allow the 
passage of drug carriers ranging from 10 to 500 nm in size depending on the tumor type and 
its location in the body. This preferential distribution to the tumor site facilities the eventual 
release of pharmaceutical agent from the carrier system (Figure 1-3). Particles with an 
appropriate size must have properties to provide a long circulation time. Longer circulation 
times can be achieved by surface modification of nanoparticles with polymers with 
hydrophilic nature such as polyethylene glycol (PEG). There are more aspects to the EPR 
effect than initially defined, which can give a better understanding of sophisticated processes 
in cancerous tissues[15]. 
 
Figure 1-3: accumulation of nanoparticles in tumor cells via EPR effect    
 
1.3.2.1. EPR fundamentals 
In a solid tumor, blood vessels are irregular. The reason for this deficiency is that when 
a solid tumor reaches a certain size, the normal vasculature in its vicinity is not able to 
provide all the required oxygen supply for the tumor’s proliferation. When cells start to die, 
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they produce growth factors that trigger the budding of new blood vessels from surrounding 
capillaries. This leads to the rapid formation of new irregular blood vessels in discourteous 
epithelium which lacks basal membrane of a normal tissue [16, 17].    
The enhanced retention component of the EPR effect can be described as follows: in 
healthy tissues, the extracellular fluid is continuously drained to the lymphatic vessels. This 
continuous draining, the renewal of interstitial fluid and the recycling of extravasated solutes 
push the colloids back into circulation, whereas in tumors, the deficiency in lymphatic 
function and the minimal uptake of interstitial fluid inhibit the return of colloids to the blood 
stream by convective force. Therefore, nanoparticles that have reached the perivascular site 
accumulate in tumor [16, 18].      
1.3.2.2. Long circulating nanoparticles  
 PEGylation provides hydrogen bonding between water molecules and the ether 
oxygens of PEG. The tightly bound water molecules around PEG chains form a hydrated layer 
around the particle; this minimizes the interactions between nanoparticles and plasma 
protein [19] which prevents opsonization of the particles by the reticulo-endothelial system 
(RES). PEG masks the surface of nanoparticles by reducing protein and plasma adsorption to 
the nanoparticle, inhibiting recognition of PEGylated nanoparticles as foreign objects in the 
blood stream so the particles can circulate for a longer time. Longer circulation allows the 
particles to be targeted to the cancerous cells by active or passive targeting. PEGylation can 
be achieved by several approaches including adsorption of PEG-containing polymers on the 
surface of nanoparticle, direct conjugation of PEG to the nanoparticles or by using block 
copolymers, which have PEG in their backbone for forming the nanoparticle [15, 19].  
 
1.3.3. Magnetic particle in biomedicine 
 Superpara-magnetic iron oxide nanoparticles (SPIO-NPs) are composed of iron oxide 
cores with the property to be targeted to the desired area through applying an external 
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magnetic field. Strong permanent magnets like neodymium iron boron (Nd-Fe-B) are widely 
used for this purpose. Particles with super paramagnetic characteristics have a diameter 
below ~	30 − 40	݊݉ which means that once the magnetic field is removed, they do not 
show any magnetization properties. This feature is very important in clinical applications, 
because if the particles do not lose their magnetic properties after removing the magnetic 
field, they tend to aggregate and can be easily recognized by macrophages [6, 20]. Moreover, 
SIPO-NPs are considered to be benign to the body mainly because under acidic condition, 
iron oxide is dissolved in the body and forms	ܨ݁ଷା. This increased number of ferric ions adds 
up to natural ion storage in the body which is 3-5 grams for an adult human [21]. The 
targetability, together with benignity to the body are two main reasons making SPIO-NPs 
increasingly attractive in biomedical applications. SPIO-NPs have provided promising features 
in cancer research as carriers in targeted drug delivery systems, tumor imaging, cancer 
hyperthermia therapy and other techniques [22].  
During the past decades, magnetic nanoparticles and microparticles have been 
developed to retain drug-loaded particles from blood circulation and deliver it to a specific 
site in vivo. This reduces the distribution of cytotoxic drug leading to a decrease in side 
effects. The localized targeting of the drug also reduces the required dosage[23]. This drug 
delivery technique can be used in the case of solid tumors close to the surface of the body 
because the strength of magnetic field decreases with distance [20]. 
Magnetic nanoparticles can couple with other targeting strategies for more efficient 
outcome. Magnetic nanoparticles can passively accumulate in many tumor tissues via the 
EPR effect owing to their nanosize. Moreover, tumor-selective ligands can be attached to the 
surface of magnetic nanoparticles to specifically bind to moieties that are over-expressed on 
the tumor cells. This facilitates active targeting of magnetic particles [24].      
1.4. Magnetic drug delivery 
Magnetic drug delivery conceptualizes targeting therapeutic agents by either attaching 
the drug to the surface of magnetic nanoparticle or encapsulating the drug within a 
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nanocomposite mixture of a polymer and magnetic nanoparticle. The approach of interest in 
this study lies in the encapsulation of cytotoxic drug along with magnetic nanoparticles inside 
a polymer matrix (Figure 1-4). Also, the presence of polymer provides a site for anchoring 
therapeutic drugs or DNA for targeted gene deliver [25].  
The large surface area of SPIO-NPs provides the possibility of enhanced covalent 
attachment of various receptors, antibodies and ligands to bind to specific targets and to 
release the drug with an appropriate dose [6]. In a recent research, R11 peptides were 
conjugated to poly (N-isopropylacrylamide-acrylamide-allylamine) nanoparticles with iron 
oxide core for active targeting of drugs for prostate cancer therapy [26].  
Once the drug has been incorporated into the nanoparticles and placed in vivo, these 
magnetic nanocomposites are retained at the target site using high-field rare earth magnet 
[25]. In order to direct the magnetic drug carrier successfully at the target site, the external 
magnetic force should suppress the blood flow pressure in arteries and capillaries [20]. After 
concentrating at target, the drug is released by either changing the physiological condition 
such as pH or temperature or by enzymatic activity [23].  
Biodegradable polymer shell carries the drug by either adsorption or entrapment. The 
incorporation of therapeutic agent and SIPO-NPs in to the polymer shell can be achieved by 
several techniques such as nano/micro emulsion method, nanoprecipitation method and 
micelle formation. Self-assembly and nanoparticle formation of amphiphilic block copolymers 
are promising routes in the formation of multifunctional nanoparticles for imaging and drug 
delivery applications. In order to enhance the targeting efficiency, the polymer coating can 
be further functionalized with molecules such as biotin or avidin, which are attach points for 
targeting antibodies to the carrier complex [23, 27].  
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Figure 1-4: encapsulation of hydrophobic drug along with iron oxide nanoparticles inside a polymer matrix 
  
1.4.1. Colloidally stabilized SPIO particles for polymeric drug delivery systems 
SIPO-NPs tend to agglomerate due to their large surface area to volume ratio and 
strong dipole-dipole attraction in both magnetic field and biological medium. This leads to 
heterogeneous size distribution and rapid clearance from blood stream. To overcome these 
complications and form a homogenous solution, SIPO-NPs are coated with suitable molecules 
or polymers. This homogenous solution is called ferrofluid. Steric and electrostatic repulsive 
forces provided by these agents stabilize the particles in the suspension [28]. The molecules 
used for stabilizing the SIPO-NPs should be biocompatible and biodegradable idyllically. 
However, surfactants such as oleic acid, lauric acid and alkane sulphonic acids are the most 
commonly used molecules. Dimension and surface charge of the particle are other important 
factors in the stability of SPIO-NPs. Particle size should be sufficiently small so that 
sedimentation by gravity can be avoided. High surface charge provides dispersion stability 
due to electrostatic interaction [23].    
The nature of functional groups on the surface of SPIO-NPs mostly determines the 
surface charge of the particle. The surface charge can be measured quantitatively as an 
electrical potential in the interfacial double-layer on the surface of nanoparticles in 
suspension. A high zeta potential value, either negative or positive, indicates that the SPIO-
PNs are stable in dispersion due to the electrostatic interactions [23].  
1.4.2. SPIO-NP synthesis  
The most common method for SPIO-NP synthesis is the co-precipitation method which 
involves addition of base to aqueous solution of ferrous ( ܨ݁ଶା) and ferric ( ܨ݁ଷା) in a 1:2 
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stoichiometry. The result is a black precipitate of spherical magnetite nanoparticles with 
uniform size. The size and shape of nanoparticles can be tailored by choosing the appropriate 
type of salts (e.g. chlorides, sulphates, nitrates, perchlorates, etc.), adjusting ܨ݁ଶା and ܨ݁ଷା 
ratio and controlling pH and ionic strength of media. It should be noted that the reaction 
needs an oxygen-free environment; otherwise, the magnetite can be further oxidized to 
ferric hydroxide [29]. The synthesis can be conducted in the presence of some surface- 
complexing agents, which can provide colloidal stability or biocompatibility. Dextran, Oleic 
acid and polyethylene glycol (PEG) are among these several SPIO-complexing agents [30].   
Recently, the microemulsion technique has been adapted to synthesize-NPs. This 
technique has the ability to control the size and shape of the particles more preciously. 
Water in oil is a more common microemulsion technique for SPIO-NP synthesis. In this 
method, iron salts aqueous nanodroplets are enclosed within surfactant layer and dispersed 
in an organic phase to form reverse micelle. Adding alkaline nanodroplets to this, results in 
the formation of SPIO-NPs within the micelles [30, 31]. 
 
1.4.3. Applicable polymers in drug delivery systems 
Designing polymeric drug delivery systems requires a through consideration of 
polymer’s biocompatibility and biodegradability. Until now, there has been no precise 
definition or accurate method of determining the biocompatibility due to the intricate nature 
of interaction between materials and biological systems. In spite of that, a criterion such as 
acceptance by a living organism can be applied to evaluate biocompatibility. By this definition, 
in a biocompatible response, toxicity as well as inflammatory, possible immune response and 
protein adsorption should be reduced to the smallest possible amount. In a biodegradable 
polymer system, degradation products of a polymer do not evoke immune or toxic response 
[32]. 
 There are two classes of biodegradable polymers based on their degradation 
mechanism; hydrolytically degradable polymers and enzymatically degradable polymers. 
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Most of the naturally occurring polymers undergo enzymatic degradation while polymers 
with labile chemical bond in their backbone are subjected to hydrolytic degradation. 
Functional groups such as esters, orthoesters, anhydrides, ureas, etc. may undergo hydrolysis. 
There are two general mechanisms for synthesizing hydrolytically sensitive polymers for 
biomedical applications; step (condensation) polymerization and chain (addition) including 
ring opening polymerization. Condensation mechanism is used to synthesize different 
hydrolytically sensitive polymer classes, such as polyanhydrides, poly (ortho esters) and poly 
urethanes [33].  
 Several biodegradable polymer systems have been pre-clinically investigated during 
the past decades for localized chemotherapy. These systems include both naturally occurring 
and synthetic polymers such as polysaccharides (chitosan, alginate and hyaluronan), protein-
based polymers (collagen, gelatin and albumin), polyesters and polyanhydrides. Among these 
different classes of biodegradable polymeric drug carrier systems, only a few polymer-based 
formulations have reached clinical testing. Poly (lactic-co-glycolic acid) (PLGA) based localized 
injectable delivery system and implantable polyanhydride copolymer systems for brain 
cancer treatment are among these clinically tested systems [34-36]. 
1.4.3.1. Natural polymers 
Natural polymers are promising for localized chemotherapeutic delivery systems since 
they have great biocompatibility and the degradation products are non-toxic and non-
immunogenic. However, some complications associated with their purification, 
immunogenicity and the possible disease transformation from their source organism to 
humans exist [34]. 
1.4.3.2. Polyesters 
Polyesters are the earliest and most extensively investigated class of biodegradable 
polymers. Depending on monomer unit, polyesters can be synthesized from various 
monomers via ring opening and polycondensation polymerization [33]. Among this class of 
polymers, poly (lactic acid-co glycolic acid) (PLGA) is the most investigated polymer. PLGA has 
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been used broadly for designing different localized delivery systems such as microparticles 
and implants. Despite the fact that polyesters’ acidic degradation products can lead to local 
irritation and instability of the drug being delivered, polyester-based drug delivery systems 
such as PLGA are considered biocompatible and biodegradable [34].  
1.4.3.3. Polyanhydrides 
Polyanhydrides undergo hydrolytic degradation due to the highly sensitive aliphatic 
anhydride bond in their backbone. The hydrophobic nature of the polymer, combined with 
hydrolytically labile backbone, prevents water penetration to polymer matrix, leading to 
surface erosion of the polymer. This hydrolytic instability, together with surface-eroding 
characteristic, makes this class of polymers attractive for controlled drug delivery systems. 
The important characteristic of polyanhydrides is that in contrast to polyesters, they degrade 
to products which are not cytotoxic or inflammatory. This material was approved by US FDA 
as a drug delivery carrier in 1966 following extensive in vitro and in vitro drug release and 
biocompatibility evaluations [33, 34, 37, 38]. 
Both homo- and co-polyanhydrides with different properties have been synthesized by 
melt condensation method. The copolymerization of aliphatic polyanhydride like poly 
(sebacic anhydride) (PSA) with hydrophobic aromatic polymer residues have been 
investigated to design polymeric systems with controllable degradation rate [33]. 
1.4.4. Methods for designing magnetic drug carriers 
Encapsulating drug molecules along with SPIO-NPs within the polymer coating 
envelope can be obtained using different methods. Gomez-Lopera et al. described a double-
emulsion method for preparing colloidal particles with magnetic core and a biodegradable 
poly (DL-lactide) polymer shell. The technique includes formation of water in oil emulsion of 
an aqueous solution of a hydrophilic drug and/or an aqueous suspension of magnetic 
particles dispersed in an organic solution of polymer. This emulsion is used to prepare the 
second emulsion in an aqueous surfactant solution. The resultant colloidal particles were 
both responding to magnetic field and useful as drug delivery system [39]. 
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In a more recent research, an emulsion-diffusion-evaporation technique was used to 
render nanocarriers loaded with SPIO-NPs and doxorubicin (SPIO/DOX-NP) and nanoparticles 
loaded with SPIO-NPs and paclitaxel (SPIO/PTX-NP). The SPIO-NPs were surface-modified 
with oleic acid and dispersed in dichloromethane (DCM) and the three polymers used for the 
encapsulation of drugs and SPIO were: PLGA, PLGA-PEG, and PCL-PEG. The organic solution 
contained polymer, SPIO-NPs and the drug. This solution was emulsified by adding the 
organic phase to an aqueous solution containing a surfactant followed by sonication. The 
mixture was then added drop-wise and under magnetic stirring to another aqueous phase 
contacting surfactant and stirred overnight letting the organic solvent evaporates (Figure 
1-5)[40]. 
 
Figure 1-5: nanocarriers loaded with SPIO-NPs and drug [40] 
In a different research, Filippousi et al. used the nanoprecipitation method to load taxol 
and SPIO-NPs within a polymer matrix. Methoxy poly (ethylene glycol)-poly (propylene 
succinate)-methoxy poly (ethylene glycol) (mPEG-PPSU-mPEG) and taxol were dissolved in 
tetrahydrofurane (THF) and the SPIO-NPs were dispersed in THF by sonication. By diffusion of 
this solution into the aqueous phase, multifunctional nanoparticles were formed [41].   
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1.5. Considerations for designing polymeric magnetic drug delivery systems 
When SPIO-NPs are used as drug carriers, size, morphology and charge of the carrier 
system should be closely investigated. These parameters determine the behavior of drug-
loaded nanoparticles in the blood stream and affect blood circulation time as well as 
bioavailability of the particles in the body. Additionally, magnetic properties and 
internalization of the particles depend on the size of particles. Particles with a size over 200 
nm are concentrated in spleen and, consequently, removed by phagocyte system whereas 
particles smaller than 10 nm in diameter by renal clearance [29]. 
1.6. Experimental techniques  
This chapter has a closer look on the experimental techniques used to characterize the 
multifunctional particle with a SIPO-NP core and a biodegradable polymer shell and 
introduce the biodegradable polymer used for encapsulation of SPIO core.   
1.6.1. Introducing Poly (Sebacic anhydride)-block-methyl ether poly (ethylene glycol) 
(PSA-mPEG) 
As mentioned in the introduction section, poly anhydrides including poly (sebacic 
anhydride) provide a controlled drug delivery system for pharmaceutical agents by surface 
erosion besides polyanhydrides and their degradation products are highly biocompatible.[42] 
Due to these important characteristics, (PSA-mPEG) was chosen as the biodegradable 
polymer shell for encapsulating SIPO-NPs. The block-copolymer was synthesized via melt-
condensation method using sebacic anhydride pre-polymer and commercial poly (ethylene 
glycol) methylene ether (mPEG). The introduction of PEG in copolymer formula adjusts the 
release rate and hydrophilic properties of the drug delivery system. The chemical structure of 
the copolymer is depicted below Figure 1-6[42]. 
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Figure 1-6: chemical structure of PSA-mPEG  
1.6.2. Nanoparticle characterization 
The focus of this study is on the characterization of these multifunctional nanocarriers 
rendered by incorporation of SIPO-NPs into a biodegradable polymer shell. Size, morphology, 
stability, and iron oxide content of these nanocarriers were studied with appropriate 
experimental techniques. Methods used to study these features are: dynamic light scattering 
(DLS), zeta potential, transmission electron microscopy (TEM), inductively coupled plasma 
mass spectroscopy (ICP-MS) and high-performance liquid chromatography (HPLC). Here we 
discuss the theory and background of zeta potential and dynamic light scattering 
measurement more closely.  
1.6.2.1. Zeta potential 
Zeta potential gives an indication about the potential stability of a colloidal system. A 
large negative or positive potential (> ±30) results in electrostatic repulsion between the 
particles, which leads to a greater stability of the particles. By definition, zeta potential of a 
colloidal system is the potential at the edge of the electrical double layer and it represents 
the effective surface charge of the particles. In ionic solutions, charged particles have a layer 
of ions, strongly bound to their surface. A second layer comprise of loosely associated ions 
diffuses around the first layer. These two layers are known as electrical double layer. When 
particles move this double layer, the shell is also moved along with the particle [43, 44]. 
In a zeta potential measurement, the electrophoretic mobility of nanoparticles is 
determined upon applying an electrical field. Electrophoretic mobility of a particle is the 
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velocity by which nanoparticles move in a solution. The zeta potential can be determined by 
equation 1:     
૆ = ૝ૈિஜ
ઽ۳
				        1 
Where ߦ	is the zeta potential (mV), ߟ is the viscosity of the dispersion medium (P), µ is the 
migration velocity (ܿ݉ ݏ⁄ ), ߝ is the dielectric constant of the dispersion medium, and E is the 
potential gradient (Voltage applied/distance between electrodes) [45]. 
1.6.2.2. Dynamic light scattering (DLS) 
DLS determines time-dependent properties such as diffusion coefficient, hydrodynamic 
radius and its distribution by dynamic changes of scattered light intensity. This random 
fluctuation in scattered light intensity is due to the Brownian motion of molecules in the 
solution which is caused by constructive or sometimes instructive light scattered from the 
molecules in the solution. Detecting these time-dependent fluctuations gives the possibility 
to explore the relaxation of concentration fluctuations through equilibrium at length scale 
of	ݍିଵ. 
ࢗ = ૝࣊.࢔࢙
ࣅ
ܛܑܖ	(ࣂ
૛
)    2  
Here q is the wave vector, ݊௦ is the refractive index of the solution, λ is the wavelength of 
scattering light in a vacuum and ߠ is the	 scattering angle. If the scattered field obeys 
Gaussian statistics, the experimentally obtained normalized intensity autocorrelation 
function ݃ଶ(ݍ, ݐ)  is directly related to the first order electric field autocorrelation function 
݃ଵ(ݍ, ݐ)  by the Sigert equation: 
ࢍ૛(ࢗ, ࢚) = ૚ + ࡮|ࢍ૚(ࢗ, ࢚)|	૛     3 
B (≤1) is an empirical factor. The correlation function has been described by a single 
exponential followed by the stretched exponential at longer times.  
ࢍ૚(ࢗ, ࢚) = ࡭ࢌࢋ࢞࢖ቂ−࢚ ࣎ࢌൗ ቃ+ ࡭࢙ࢋ࢞࢖ൣ−(࢚ ࢙࣎ࢋൗ )	ࢼ൧    4  
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࡭ࢌ + ࡭࢙ = ૚         5 
ܣ௙ is the amplitude of the fast mode and ܣ௦ is the amplitude of the slow mode. ߬௙ and ߬ ௦௘are 
the fast relaxation time and the effective slow relaxation time, respectively.  ߚ (0< ߚ ≤1) is 
the measure of the width of the distributions of relaxation times. The slow relaxation time is 
calculated by the following equation: 
࢙࣎ ≡ ∫ ࢋ࢞࢖ൣ−(࢚ ࢙࣎ࢋൗ )	ࢼ൧ஶ૙ dt= (࢚ ࢙࣎ࢋൗ )ડ(૚ ࢼൗ )     6 
Where Γ is the gamma function. 
When the fast and slow relaxation modes are diffusive (ݍଶ dependent):  
ࡰࢌ = ૚ ࣎ࢌ	ൗ ࢗ૛      7 
 The apparent hydrodynamic radii ܴ௛  can be calculated by using Stokes-Einstein equation: 
		ࡾࢎ = ࢑࡮ࢀ૟࣊ࣁࡰ               8 
݇஻ is the Boltzmann constant,	ܶ is the absolute temperature and ߟ	 is the solvent viscosity 
[46]. 
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2. Experimental 
2.1 .Pre-polymer synthesis 
Sebacic acid (20.0g) was refluxed with acetic anhydride (200 ml) at 140	℃ for 45 
minutes under nitrogen atmosphere. Acetic acid and unreacted acetic anhydride were then 
removed by rotary evaporator at 60℃. The resulting oligomers were recrystallized overnight 
at 0	℃   from dry toluene. The crystals were subsequently added to 200 ml extraction solvent 
(1:1 dry petroleum ether/di ethyl ether) to extract traces of acetic anhydride and toluene. 
The purified pre-polymer was dried overnight in vacuum at room temperature (88.5% yield) 
[47]. 
2.2. Block copolymer synthesis 
Sebacic anhydride pre-polymer (PSA) (4.0g) and poly (ethylene glycol) monomethyl 
ether (mPEG) (3.0 g) (ܯ௪=2000) were placed in a flask at 180	℃, in vacuum for 2 hours to 
perform melt-condensation. The raw product was dissolved in 40 ml dry chloroform and 
precipitated afterwards in 200 ml anhydrous diethyl ether. The purified PSA-mPEG was dried 
overnight in vacuum at room temperature (81.4% yield)[48]. 
2.3. Characterization of the pre-polymer and copolymer 
The chemical structure of pre-polymer and block copolymer was confirmed by ܪ	ଵ  NMR 
and the spectrum was recorded with a Bruker DRX 500 MHz spectrometer. A 1 wt % polymer 
solution in ܥܦܥ݈ଷ was used for the measurement. 
FTIR spectroscopy was done by a Perkin Elmer spectrum one spectrometer to confirm 
the chemical structure of PSA, PSA-mPEG and its degradation products. The polymer samples 
pellets were prepared using KBr. 
Number average molecular weight (ܯ௡ ), weight average molecular weight, and 
polydispersity index (PDI) of the synthesized block copolymer were measured by gel 
permeation chromatography (GPC) (Measurements were done at KTH) using 
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polymethylmethacrylate (PMMA) as standard for calibration. Measurements were done in 
triplicate and the results are reported in average.     
2.4. In vitro hydrolytic degradation 
The degradation study of PSA-mPEG was performed in 10 ml phosphate saline buffer 
(PBS) of pH 7.4.  Three samples containing 200 mg polymer were prepared for three time 
intervals. The samples were placed in an incubator shaker (Edmund Bühler GmbH model 
TH30) at 75 rpm and 37℃. A 1-ml aliquot of PBS was replaced by fresh PBS every 24 hours. 
After 3 days the PBS in the first sample was removed and then lyophilized and kept at -80℃ . 
The second sample was treated with the same procedure after 6 days and the third one after 
10 days. The degradation products were further characterized by FTIR spectroscopy. The first 
and third samples were chosen to investigate the change in molecular weight by GPC. 
Measurements were done in triplicate and the average molecular weight was reported.  
2.4.1. Phosphate buffer saline (PBS) preparation 
PBS was prepared by dissolving 2.175 g	ܰܽܥ݈, 0.068 g	ܭܪଶܲ ସܱ, and 0.284 g	ܰܽଶܪܱܲସ 
in 200 ml deionized water. The pH was adjusted to 7.4 either by adding 1N ܪܥ݈	or 1Nܱܰܽܪ. 
The final volume was then brought to 250 ml by adding deionized water[49]. 
2.5. Nile red loaded nanoparticles 
To evaluate the drug loading properties of PSA-mPEG nanoparticles, nile red was used 
as a hydrophobic drug model. This drug model was encapsulated within PSA-mPEG 
nanoparticles by nanoprecipitation method. Nile red stock solutions of 0.005 (w/v) % and 
0.01 (w/v) % in tetrahydrofuran (THF) were prepared. PSA-mPEG (20mg) was dissolved in 
4600 ߤl THF and 400	ߤl nile red (0.01 (w/v) %) was added to the polymer solution. From 
0.005 (w/v) % nile red stock solution, 300 ߤl was added the same way to 4700 ߤl of polymer 
solution in THF containing 20 mg PSA-mPEG. 
The organic solution containing dye and polymer was added drop-wise by needle and 
syringe to 15 ml filtered (0.1	ߤ݉ MILLEX® VV) deionized-water (non-solvent) under magnetic 
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stirring at room temperature. THF was removed afterwards by a rotary evaporator. Resulting 
nile red-loaded nanoparticles were recovered by ultra-centrifugation (Beckman L-80 XP 
ultracentrifuge) for 1 hour with 25000 r.p.m at 4℃ . The supernatant which contained non-
encapsulated nile red was discarded and nanoparticles were then lyophilized and stored at 
4℃. 
2.6. Nile red encapsulation efficiency and content 
The amount of nile red entrapped in PSA-mPEG nanoparticles was measured by HPLC 
(Perkin Elmer Series 200). 1 mg of accurately weighted nanoparticles was suspended in 1 ml 
of ethanol to extract the encapsulated nile red. For complete extraction, the suspension was 
sonicated for 10 minutes and the nanoparticles were separated by a spin down centrifuge. 
The amount of encapsulated nile red was measured by injecting 10 ߤl of supernatant and 
detection at 550 nm using a calibration curve made based on peak area and absolute amount 
of nile red. HPLC measurements were done at analytical chemistry group at UIO.  
݁݊ܿܽ݌ݏݑ݈ܽݐ݅݋݊	݂݂݁݅ܿ݅݁݊ܿݕ(%) = ܽ݉݋ݑ݊ݐ	݋݂	݈݊݅݁	ݎ݁݀	݅݊	݊ܽ݋݌ܽݎݐ݈݅ܿ݁ݏ	
݅݊݅ݐ݈݅ܽ	ܽ݉݋ݑ݊ݐ	݋݂	݈݊݅݁	ݎ݁݀
× 100 
ܦݕ݁	ܥ݋݊ݐ݁݊ݐ ቀ%ݓ
ݓ
ቁ = ܽ݉݋ݑ݊ݐ	݋݂	݈݊݅݁	ݎ݁݀	݅݊	݊ܽ݊݋݌ܽݎݐ݈݅ܿ݁ݏ
ܽ݉݋ݑ݊ݐ	݋݂	݊ܽ݊݋݌ܽݎݐ݈݅ܿ݁ݏ
× 100 
2.7. SPIO loaded polymeric nanoparticle preparation 
SPIO loaded polymeric nanoparticles (SPIO-PNPs) were prepared by the 
nanoprecipitation method using PSA-mPEG as the polymeric vehicle. SPIO-NPs had an 
average diameter of 10 nm and the surface of the particles was hydrophobically modified 
with oleic acid. SPIO-NPs (5 mg/ml) in THF (sample 1=40 ߤl, sample 2=80 ߤl, sample 3=120 ߤl, 
sample 4= 160 ߤl) were added to the solution of 20 mg PSA-mPEG in THF (sample 1=4.960 ml, 
sample 2=4.920 ml, sample 3=4.880 ml, sample 4= 4.840 ml). Later, the suspensions were 
added drop-wise to 15 ml of filtered deionized water (0.1	ߤ݉ MILLEX® VV)  by needle and 
syringe under constant stirring of an overhead stirrer at 900 r.m.p (Ruhrwerk EUROSTAR 
power control-visc P7). THF was further removed by a rotary evaporator (Figure 2-1). 
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Figure 2-1: Schematic of SPIO-NPs loaded in PSA-mPEG by nanoprecipitation method   
2.8. Purification of SPIO loaded nanoparticles 
After solvent removal, nanoparticles were collected by ultracentrifugation (Beckman L-
80 XP ultracentrifuge) at 25000 r.p.m for 60 minutes at 4℃. The supernatant was discarded 
and the nanoparticles were suspended in 4 ml solution of 0.05 Mܪܱܰଷ. In order to remove 
unloaded SPIO-NP, the suspension was neutralized with PBS pH 7.4. The resulting iron 
hydroxide aggregates were eliminated by mild centrifugation (2000 r.p.m for 15 minutes). 
The loaded SPIO-PNPs in the supernatant were collected by ultracentrifugation (27000 r.p.m 
for 90 minutes at 4℃ and re-suspended in 5 ml of deionized water [50]. 
The resulting suspension was stored for studying its size, morphology and zeta 
potential while for studying iron oxide content of SPIO-PNPs the suspension was lyophilized 
and stored at 4℃ for further measurement. 
 
2.9. Inductively coupled plasma spectroscopy (ICP-MS) analysis 
Iron content of SPIO-PNPs was measured using ICP-MS. Analysis was performed using a 
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Thermo Finnigan Element 2 instrument (Bremen, Germany). The measurements were done 
at chemistry department of NTNU.  
To correlate the iron concentration obtained from ICP-Ms analysis to the amount of 
iron oxide particles, the following relation was used[29] : 
1 particle of SPIO = 62896 iron atoms 
1 g of SPIO-NPs = 1.71 × 10ଵ଻particles 
The iron oxide content in SPIO loaded polymeric nanoparticles is calculated by the 
below relation [50] : 
ܫݎ݋݊	݋ݔ݅݀݁	ܿ݋݊ݐ݁݊(%) = ݉ܽݏݏ	݋݂	݅ݎ݋݊	݋ݔ݅݀݁	݅݊	ܵܲܫܱ − ܲܰܲ
݉ܽݏݏ	݋݂	ܵܲܫܱ − ܲܰܲ
× 100 
2.10. Dynamic light scattering (DLS) 
DLS measurements were carried out to determine the size of SPIO-PNPs. The 
experiments were conducted using an ALV/CGS-8F multi-detector compact goniometer 
system with eight off fiber-optical detection units made by ALV-GmbH, Langen, Germany. 
The laser light (He-Ne,ߣ = 632.5 nm) was focused on the sample cell (10 mm NMR tube). 
The temperature control of the cell was provided by a thermostat, circulating water around a 
cylindrical quartz container filled by a refractive index-matching liquid (cis-decalin). The 
intensity of scattered light from the sample measured simultaneously at eight scattering 
angles in a range of 22-141°. All the sample solutions were filtered in the atmosphere of filter 
air through a 5 ߤ݉ filter (Millipore) into the pre-cleaned NMR tubes to avoid entering dust to 
the solutions. 
2.11. Transmission electron microscopy (TEM) 
The morphology of nanoparticles was investigated by TEM. For this, the suspension of 
particles was absorbed on hexagonal copper grids for 2 minutes followed by washing three 
times with MQ-water and further staining with 3% uranyl acetate. The imaging was 
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performed with a Philips transmission electron microscope CM100 (Philips, Eindhoven, The 
Netherlands). The images were recorded digitally with a Quesma TEM CCD camera (Olympus 
Soft Imaging Solution, Germany) and iTEM software (Olympus Soft Imaging Solution, 
Germany).   
2.12. Zeta potential 
The zeta potential measurements were conducted on a Malvern Zetasizer Nano ZS 
(Malvern Instrument Ltd. Worcestershire, UK). The sample cell used was a dip-cell, including 
palladium electrodes with 2mm spacing, one PCS115 cuvette, and a cap. First standard 
solution of -68 mV was measured three times after that measurements continued on 600ߤl 
of sample solutions in triplicate.    
2.13. In vitro cytotoxicity 
MDA-MB-231 breast cancer cells were used to determine the cell cytotoxicity. The cells 
were cultured in RPMI 1640 cell culture medium (Lonza, Verviers, Belgium) containing 10% 
fetal bovine serum and 1% penicillin-streptomycin. Cells were grown by incubation in T75 
flask at 37℃	in humidified atmosphere with 5% ܥܱଶ .  After getting enough confluence, 1ml 
trypsin with a concentration of 200 mg/l was added to dissociate the cells. Trypsin was 
further neutralized by 5 ml of cell culture medium. 
 To obtain the number of viable cells per milliliter, 100	ߤl of cell suspension was mixed 
with 100	ߤl of trypan blue solution, subsequently 10	ߤl of this solution was added to a cell 
counting chamber and viable cells were counted three times under the microscope at 1000 
magnification. Under the microscope a grid of 9 squares is visible. The microscope then 
should be focused on one of the 4 outer squares in the grid (Figure 2-2) which contains 16 
smaller squares. The unstained cells are counted in this square. Nonviable cells are stained by 
trypan blue while viable cells remained unstained. The average of these three time readings 
was multiplied by 10ସ to obtain the number of  viable cells per milliliter[51].  The three 
readings for trypan blue assay were 61, 62 and 67 therefore the average concentration of 
viable cell was 63× 10ସ ݈݈ܿ݁ ݈݉⁄ . 
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Figure 2-2 : Cell counting by trypan blue assay using a cell counting chamber  
Harvested cells were seeded in a 96-well plate at the density of 5× 10ଷ  viable cells 
/well. According to trypan blue assay results, the required density of viable cells corresponds 
to 175	ߤl cells for 20 wells. This amount was added to 1825 	ߤl cell culture medium and 
100	ߤl of this mixture was seeded in each 20 plates followed by 24 hours incubation at 
37℃	in humidified atmosphere with 5%ܥܱଶ. To reduce evaporation during incubation, cell-
seeded wells were surrounded by wells contacting 200 ߤl  of culture medium. Blank PSA-
mPEG NP (PNP), SPIO-NP and SPIO-PNP suspensions were made by adding lyophilized 
nanoparticles to cell culture medium with concentration ranging from 1 to 2 ߤg/ml. 24 hours 
post incubation, 100ߤl of nanoparticle solutions were added to the wells with seeded cells 
according to the Figure 2-3.   
Cell viability of nanoparticle treated cell was assessed by MTS [3-(4, 5-dimethylthiazol-
2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium] assay. 20 µl  MTS 
(CellTiter 96® Promega, Madison-USA) was added to each cell and incubated for 3 hours. The 
cell viability was further determined at three time intervals (24 hours, 48 hours and 72 hours). 
This method is based on bio-reduction of tetrazolium salt to an intensely colored formazan 
with UV absorbance at 490 nm. The quantity of formazan product measured by UV 
spectroscopy is directly proportional to the number of living cells. The absorbance of the 
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produced formazan was measured by plate reader at 490 nm (Wallac Victor, Turku-Finland). 
The cell viability was calculated using following formula: 
݈݈ܿ݁	ݒܾ݈݅ܽ݅݅ݐݕ(%) = ܾܽݏ݋ݎܾܽ݊ܿ݁	݋݂	ݐݎ݁ܽݐ݁݀	݈݈ܿ݁ݏ
ܾܽݏ݋ݎܾܽ݊ܿ݁	݋݂	ݑ݊ݐݎ݁ܽݐ݁݀	݈݈ܿ݁ݏ
	× 100 
 
Figure 2-3 : Cell seeding pattern in 96-well plate 
2.14. In vitro Cellular uptake of SPIO loaded nanoparticle 
To assess cellular uptake of SPIO loaded PSA-mPEG (SPION-PNPs) nanoparticles, the 
MDA-MB-231 cancer cells were seeded in 6-well plate at a density of 6× 10଺. The cells were 
allowed to grow for 24 hours; subsequently, the medium was replaced by fresh medium 
containing SPION-PNPs nanoparticles. 24 hours post addition of nanoparticles the medium 
was removed and the cells were washed with 1 ml PBS. The cells were fixed by 2% 
glutaraldehyde in cacodylate buffer pH 7.0 and left overnight at 37℃ and then cross-
sectioned in department of biology at UIO. The cross-sectioned cells were imaged by TEM 
afterwards. 
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3. Results and discussion 
3.1. Characterization of pre-polymer and block copolymer 
The chemical structure of PSA-mPEG block-copolymer and PSA pre-polymer is 
confirmed by ܪܰܯܴ	ଵ   and FTIR spectra (Figure 3-1) and (Figure 3-2). The chemical shifts at 
ߜ=1.3, 1.6, 2.2, and 2.4 ppm are well resolved and correspond to hydrogen atoms of PSA 
functional groups. The peak at ߜ=3.6 ppm is assigned to the methylene protons on the PEG 
block which was introduced by block-copolymerization. Another chemical shift observed at 
ߜ=4.2 ppm belongs to the methylene protons of glycol next to the ester bond of sebacic 
anhydride and ethylene oxide. This can confirm the successful polymerization of PSA and PEG. 
[42].     
The FTIR spectra of sebacic acid (SA), poly (sebacic anhydride) (PSA), and poly (sebacic 
anhydride)-block-methyl ether poly (ethylene glycol) (PSA-mPEG) are illustrated (Figure 3-2). 
It reveals that absorption peaks related to asymmetric and symmetric stretching modes of 
carbonyl groups in anhydride segment developed at 1740 	 and 1813 ܿ݉ିଵ   while 
corresponding peaks of asymmetric and symmetric stretching modes of C-O for anhydride 
segments appear at 1074 and 1041 ܿ݉ିଵ respectively. The peaks at 2935-2915 ܿ ݉ିଵ and 
2854-2840 ܿ ݉ିଵ are assigned to the methyl and methylene vibrations. Absorption peaks at 
960 ܿ ݉ିଵand 1100 corresponds to symmetric and asymmetric stretching modes of C-O-C of 
ethylene glycol [42, 47]. 
The average ܯ௡ and  ܯ௪ obtained from GPC were 2497 and 2929 ݃ ݉݋݈⁄  respectively 
and the PDI was 1.17. 
3.2. In vitro hydrolytic degradation of PSA-mPEG 
PSA-mPEG undergoes hydrolytic degradation via surface erosion of PSA block in PBS 
buffer at 37℃. The conversion of anhydride bonds to acid groups is depicted in FTRI spectra 
of degraded polymers (Figure 3-2). During the degradation a strong carboxylic hydroxyl band 
appears between 2500 and 3300 ܿ݉ିଵ. This is followed by appearance of a carboxylic 
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carbonyl band at 1704 ܿ ݉ିଵwhich its intensity becomes stronger with degradation time.  
Meanwhile the characteristic peaks for anhydride segment at 1813 and 1740 ܿ ݉ିଵand C-O-C 
stretching band at 1100 ܿ ݉ିଵbecome weaker (Figure 3-3) [47, 52].  
 
Figure 3-1   ܪܰܯܴ	ଵ  spectra of (a) PSA and (b) PSA-mPEG 
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Figure 3-2  FTIR spectra of (a) sebacic acid (SA), (b) poly (sebacic anhydride) (PSA), (c) Poly (Sebacic anhydride)-
block-methyl ether poly (ethylene glycol) (PSA-mPEG) 
 
To monitor the degradation rate, the change in molecular weight was studied by GPC. 
Molecular weight (ܯ௪) of three time intervals is shown in Figure 3-4. After 3 days there was 
a 14% loss in molecular weight, this amount reached 23% after 10 days. Due to the surface 
erosion mechanism of poly (sebacic anhydride) block, the polymer was able to maintain 77% 
of its initial molecular weight after 10 days. This makes the this block copolymer applicable 
for controlled drug delivery and can provide a sustained release over long period of time[53]. 
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Figure 3-3  FTIR spectra of degradation of PSA-mPEG at (a) 0 day (b) 3rd day, (c) 6th day, and (d) 10th day 
 
 
Figure 3-4 : Change in molecular weight (ࡹ࢝) by hydrolytic degradation  
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3.3. Encapsulation efficiency  
The resulting encapsulation efficiency and dye content of nile red is summarized in 
Table 1. 
Table 1 : Characters of nile red loaded in PSA-mPEG nanoparticles by nanoprecipitation method  
Initial amount 
of dye (ࣆࢍ) 
Dye-polymer 
ratio (%) 
Encapsulation 
efficiency (%) 
Dye content 
(%) 
15 0.075 59.1 0.15 
40 0.2 55.7  0.3 
 
 As it is shown in the table above the drug content was predictably higher for larger 
initial dye usage but despite the big difference in initial dye amount of the two dye-polymer 
ratios there was not a big difference in encapsulation efficiencies. One should note that 
inevitably small amount of nanoparticles may be lost during the washing process which may 
have a slight impact in the resulting encapsulation efficiency and dye content.  
3.4. Synthesis of SPIO-loaded polymeric nanoparticle (SPIO-PNP) 
Purified SPIO-PNPs were prepared with four different loading levels of SPIO (w/w based 
on polymer): 1%, 2%, 3% and 4% by nanoprecipitation method. Table 2 summarizes size, and 
SPIO content of the prepared SPIO-PNPs. 
The average diameter of SPIO-PNPs seems to be affected by amount of SPIO 
encapsulated in these particles. SPIO content of nanoparticles and their average diameter 
was at its maximum for 2% SPIO loading whereas 4% SPIO loading which had the minimum 
SPIO content corresponds to the smallest diameter. 1% and 3% SPIO loading with close 
amount of SPIO content had approximately the same size. The same relation between 
therapeutic agent content and size of a nanoparticle  was observed in a previous study[54].  
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Table 2 : Characters of SPIO-NPs loaded in PSA-mPEG by nanoprecipitation method 
SPIO loading (%) Diameter 
size(nm) 
SPIO content (%) 
1 188 0.05 
2 266 0.08 
3 216 0.03 
4 154 0.01 
 
The size of tumor vascular pores may vary from 100 to 600 nm[55] and carrier systems 
with diameter larger than 200 nm may induce nonspecific scavenging by reticuloendothelial 
system (RES)[56], consequently particles with diameters less than 200 nm exhibit improved 
EPR effect[57]. Considering this fact and the SPIO content of the synthesized nanocarriers in 
Table 2, 1% SPIO loading seems to be an optimal platform for cancer therapy applications.  
In Figure 3-5, normalized time correlation function data at 5 scattering angles for the 
samples in Table 2 together with the corresponding curves fitted by equation 4 are illustrated. 
For all four samples the relaxation process is unimodal and the correlation function was 
fitted successfully by the first stretched exponential function in equation 4. The average ߚ 
value was 1 for all samples except for 3% SPIO loading, where the value was 0.9.      
In Figure 3-5 the decay rate ( ߬ିଵ) as a function of ݍଶ is also depicted, which discloses 
the diffusivity of the system; the slope of this plot represents the apparent diffusion 
coefficient D, which in diffusive systems is not dependent on scattering angle. By putting D in 
equation 8 the hydrodynamic radius	(ܴ௛) is determined. 
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Figure 3-5 : First-order electric field correlation function vs. time and the decay rate (τ-1) as a function of q2 for 1%, 
2%, 3% and 4%SPIO loading of SPIO-PNP solutions. 
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3.5. Zeta potential  
To explore the stability of SPIO-NPs after encapsulation with PSA-mPEG zeta potential 
measurement was conducted on SPIO-PNPs with four concentration of SPIO (1%, 2%, 3% and 
4%), blank PSA-mPEG nanoparticle (PNP) and SPIO nanoparticle without encapsulation (SPIO-
NP) (Figure 3-6) in deionized water and PBS.  
Figure 3-6 shows no sign of significant decrease in zeta potential after encapsulation 
with polymer and it seems that the nanoparticles are stable before and after encapsulation 
with polymer due to the fact that the absolute value of zeta potential is high (larger than 30 
mV) and the particles can be assumed to be electrostatically stabilized. Blank PSA-mPEG 
nanoparticles with zeta potential value about -15 mV on the other hand seems to be 
considerably less stable than SPIO loaded PSA-mPEG nanoparticles [44].    
The absolute value of zeta potential decreased considerably after re-suspending SPIO-
PNPs in PBS. This might be due to the increase in ionic strength of the system which leads to 
gradual screening of electrostatic repulsive forces [58]. 
  
Figure 3-6: Zeta potential measurement of SPIO-PNP, SPIO-NP and PNP 
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3.6. Long term stability of SPIO-loaded polymeric nanoparticles (SPIO-PNP) 
DLS was employed to measure the size of (SPIO-PNP) over course of 30 days at room 
and body temperature. The hydrodynamic radius derived from the fast relaxation time 
during the period of one month is depicted for 1% SPION-PNPs in Figure 3-7. 
The hydrodynamic radius of nanoparticles did not change considerably over time so it 
can be concluded that particles were stable during the time period [59]. Steric repulsion 
between highly negatively charged particles along with the amphiphilic structure of the di-
block copolymer can probably be named as the main reason for the stability of nanoparticles. 
Due to the surfactant-like behavior of amphiphilic di-block copolymers nanoparticles can be 
prepared by nanoprecipitation method without using stabilizers such as poly (vinyl alcohol) 
(PVA). Stabilizers are usually hard to remove and may cause toxicity [60]. 
In Figure 3-8, normalized time correlation function data at scattering angle of 107° 
together with corresponding fitted curves by equation 4 are illustrated in the form of 
semilogarithmic plots for aqueous suspension of 1% SPIO-PNPs. The measurements were 
done at 6 time intervals at temperature 25 and 37 ℃ . The decay curves fitted by aid of  
equation 4 can be described by a stretched exponential with( β>0.95) (Table 3) indicating 
almost a single exponential decay and a narrow size distribution [61]. 
In the normalized correlation functions for the 15th day with corresponding unimodal 
fitted curves at 5 scattering angles are depicted for both temperatures (Figure 3-9). The slope 
of decay rate ( ߬ିଵ) as a function ݍଶ  probes diffusion coefficient which was used to calculate 
the hydrodynamic radius of the particles. The linear correlation coefficient, R close to 1 is 
also a rather clear indication of the dominance of diffusion as a main relaxation mechanism 
of the system.  
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Figure 3-7 : Hydrodynamic radius of 1%loading SPIO-PNPs at 25 and 37℃ over one month 
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Figure 3-8 : normalized time correlation function data at scattering angle of 107°for solution of 1%loading SPIO-PNPs at 
25 and 37℃  .The curves are fitted with the aid of equation 4 
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Table 3 : ࢼ value obtained from fitting curve of correlation function at angle of 107°  at 25 and 37℃. 
 Day1 Day4 Day9 Day15 Day21 Day30 
25℃ 1 0.97 0.96 0.95 0.97 1 
37℃ 0.97 1 0.98 0.98 1 0.98 
 
 
 
Figure 3-9: First-order electric field correlation function vs. time and the decay rate (τ-1) as a function of q2 for 1% loading 
SPIO-PNP solution at 15th day 
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3.7. Transmission electron microscopy (TEM) 
The successful encapsulation of SPIO nanoparticles in polymer shell was visualized by 
Figure 3-10(a-c) shows iron oxide nanoparticle encapsulated in polymer shell. The electron 
dense iron oxide nanoparticles are clearly seen as dark regions in the micrograph which are 
surrounded by a gray-shaded polymeric shell [62]. The morphological observation of SPIO 
loaded polymeric nanoparticles by TEM shows roughly round-shaped nanoparticles. It should 
be mentioned that in morphological studies by TEM one should consider that TEM 
micrograph is not representative of the real state of nanoparticles in suspension since the 
dispersion medium is removed during sample preparation and the ‘’grape-like’’ organization 
of the particles in micrographs could be a consequence of that [63]. 
  
3.8. Cytotoxicity 
Apart from their supermagnetic properties, SPIO-NPs have attracted considerable 
attention due to their low toxicity in human body. A study conducted on breast cancer cells 
revealed that iron oxide nanoparticles coated with a surfactant are non-toxic in 
concentration range of 0.1-10 ߤg/ml while the particles show toxicity at 100 ߤg/ml[64]. 
One of the mechanisms by which iron overload can induce toxicity is via producing 
highly reactive hydroxyl radicals. SPIO-NPs are presumably degraded into iron ions by 
hydrolyzing enzymes. These iron ions can potentially pass the mitochondrial membrane and 
react with hydrogen peroxide and oxygen produced by mitochondria. This leads to formation 
of highly reactive hydroxyl radicals that could damage DNA, proteins, polysaccharides and 
lipids in vivo [65]. 
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Figure 3-10 : TEM image of (a-c) iron oxide nanoparticles encapsulated in polymer matrix (SPIO-PNP) (d)super-
paramagnetic iron oxide nanoparticles(SPIO-NPs) 
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Both SPIO and SPIO loaded polymeric nanoparticles showed negligible cytotoxic effect 
in the concentration range of 1-2 ߤg/ml up to 72 hours (Figure 3-11). The results within this 
concentration range are consistent with the previous work done on breast cancer cell lines 
[64]. The results also indicate that the oleic acid used as stabilizer on surface of SPIO-NP did 
not trigger toxicity. 
Cell viability of blank PSA-mPEG nanoparticles was also high (>85%) which is in 
agreement with the previous studies on sebacic anhydride copolymers [66] and makes this 
polymer a safe carrier for SPIO-NPs. Another interesting feature demonstrated by blank PSA-
mPEG nanoparticles is their high cell viability after 72 hours which could be an indication of 
low toxicity of degradation products of PSA-mPEG copolymer since it has been shown in this 
study that in vitro hydrolytic degradation of the copolymer has been started after 3 days.    
 
Figure 3-11 : Cell viability of blank PSA-mPEG nanoparticles (NP), SPIO-NP and SPIO-PNP with two concentrations 
(c1 and c2)   
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3.9. Cell uptake  
Since accumulation of nanoparticles in cancer cells is of great importance for cancer 
detection and treatment, TEM study on MDA-MB-231 human breast cancer cells was 
performed to visualize the presence and confinement of SPIO-PNPs within the cancer cells. 
To confirm that the nanoparticles were indeed internalized by target cells rather than simply 
binding to the surface of the cells, the nanoparticle treated cells were embedded then cross 
sectioned and studied by TEM. 
 TEM images confirmed that SPIO-PNPs with average diameter between 150-200 nm 
crossed the cell membrane via endocytic pathway and internalized inside vesicles. 
Endocytosis is a mechanism by which mammalian cells internalize small molecules, 
macromolecules, and particles and target them to sealed organelles within the cytoplasm[67]. 
Observing this internalization via endocytosis is compatible with the previous research done 
to investigate SPIO-PNPs uptake by breast cancer cells [27]. Furthermore as predicted from 
cytotoxicity experiments cancer TEM observations showed that cellular structures were well 
preserved and no visible abnormalities were observed in cells treated with SPIO-PNPs. 
Cell uptake is described as a two-step process: the first step is binding to the cell 
membrane, via cell surface receptors and the second is the actual internalization event [68]. 
The first step is demonstrated in Figure 3-12-b which shows a particle binding to the cell 
membrane before crossing it. In Figure 3-12-c and d one can clearly recognize the second 
step of the cell uptake process which is the successful internalization of particles within 
vesicles of diameter between 1.5-2 	ߤ݉. Figure 3-12-a is the image of control cell. 
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Figure 3-12 : TEM image of (a) control cell (b) particles before crossing the cell membrane (c-d)after confinement 
within the cell. 
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4. Conclusion 
Block copolymer of poly (sebacic anhydride)-block-methylether-poly (ethylene glycol) 
(PSA-mPEG) was synthesized via melt-condensation. The polymer was characterized using ܪ	ଵ  
NMR and FTIR which verified the success of copolymerization. The molecular weight 
(ܯ௪ܽ݊݀	ܯ௡) and poly dispersity index (PDI) were obtained by GPC. 
The degradation behavior of (PSA-mPEG) was studied in PBS at pH 7.4 at 37℃. As the 
degradation preceded conversion of anhydride bonds to acid and weakening of anhydride 
linkage was observed in FTIR spectra. The change in molecular weight was also investigated 
during the degradation. After 3days the polymer maintained 86% of its initial molecular 
weight this reached to 77% after 10 days. 
Nile red was encapsulated as a hydrophobic drug model. The encapsulation efficiency 
and dye content was measured by HPLC. The main focus of this study was encapsulation of 
SPIO-NP within a biodegradable and biocompatible polymer synthesized in this research. The 
successful loading of SPIO-NPs in the polymer shell was confirmed by TEM. The size and SPIO-
NPs content for four polymer-SPIO ratios were studied to find an optimal carrier system for 
cancer therapy applications. Considering the required size for reaching the tumor site, 1% 
SPIO loading was recognized to be a good carrier of choice. 
Zeta potential of SPIO-PNPs, SPIO-NPs and blank PNPs were investigated in deionized 
water and PBS. No considerable change of zeta potential for SPIO-NPs was observed after 
encapsulation with polymer shell and all the carriers except PNPs had enough surface charge 
to be stable in deionized water. The value of zeta potential of SPIO-PNPs decreased after re-
suspending them in PBS due to the screening of the charges in a medium with high ionic 
strength.   
The changes in hydrodynamic radius of SPIO-PNPs were investigated by DLS at room 
and body temperature over one month. The hydrodynamic radius did not change 
substantially during this period of time. This could be attributed to the repulsive force 
between negatively charged particles and the surfactant-like behavior of amphiphilic di-block 
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copolymer used as a matrix for encapsulation of SPIO-NPs. 
The cytotoxicity of SPIO-PNPs in two different concentrations, SPIO-NPs and PNPs were 
studied over course of three days on MDA-MB-231 breast cancer cell line. The cell viability 
for all the above mentioned systems was high (over 85%) which means that that they did not 
induce toxicity. 
The successful internalization of SPIO-PNPs was visualized by TEM. The cells were fixed 
and cross sectioned to make sure that the particles were inside the cell. TEM micrographs 
confirmed that the particles were successfully internalized and confined within vesicles via 
endocytosis mechanism. 
Magnetic nanocarriers with an iron oxide core and a biodegradable and biocompatible 
polymer shell can greatly enhance the targetability of drug delivery systems. PSA-mPEG could 
be promising for magnetic drug delivery systems due to its biocompatibility and 
biodegradability. Besides PSA block can provide a sustained drug delivery system while the 
PEG block increases the circulation time in blood stream. These magnetic nanocarrier 
systems can be combined with other targeting systems like ligand targeting to form a more 
efficient drug delivery system. 
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